Zivo Bioscience, Inc.

TROY, Mich.--(BUSINESS WIRE)-- Zivo Bioscience, Inc. (OTCID: ZIVO) ("ZIVO" or the "Company") announced today that it is transitioning its common stock to quotation on the OTCID marketplace. Zivo Bioscience began trading on OTCID as of Monday, May 11, 2026. Transitioning to OTCID is a common step for companies seeking to maintain public trading while aligning with a marketplace that offers streamlined reporting requirements, improved flexibility, and continued visibility for investors. Companies moving to OTCID typically do so to promote continued trading, maintain shareholder access to liquidity, and operate within a disclosure framework that supports their stage of growth and operational needs. The OTCID marketplace is an OTC Markets tier for companies that publish baseline disclosure and maintain current information through OTC Markets’ disclosure systems. As part of the transition, the Company will continue to make available required corporate and financial information through its OTC Markets disclosure page in accordance with applicable OTC Markets standards. “This transition supports our commitment to transparency and continued access for our shareholders,” said John B. Payne, CEO. “Completing OTC Markets’ review process and moving to OTCID allows us to focus on advancing our scientific and commercial objectives while maintaining an efficient public‑market presence.” All existing shareholders will retain their positions through the transition, and no action is required on their part. Shareholders may stay up to date on company news, announcements, and insights, please connect with us on Facebook, X, and LinkedIn, or by regularly checking the Company’s disclosure page on the OTC Markets website, where filings, financials, and updates are posted. Forward Looking Statements This news release contains forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties and should not be relied upon as predictions of future events or promises of a given course of action. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. Although ZIVO believes these forward-looking statements are reasonable as of the date made, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks that our strategic partnerships may not facilitate the commercialization or market acceptance of our products; risks that we will be unable to increase production sufficient to meet demand; risks that our products may not be ready for commercialization in a timely manner or at all; risks that our products will not perform as expected based on results of our preclinical and clinical trials; our ability to raise additional funds; uncertainties inherent in the development process of our products; changes in regulatory requirements or decisions of regulatory authorities; the size and growth potential of the markets for our products; the results of clinical trials; our ability to protect our intellectual property rights; and other risks, uncertainties and assumptions, including those described in ZIVO’s publicly available filings and disclosures, including on its OTC Markets disclosure page and, to the extent applicable, prior filings with the Securities and Exchange Commission. ZIVO is currently not subject to the filing requirements of the Securities Exchange Act of 1934, as amended. These forward–looking statements speak only as of the date of this news release and ZIVO undertakes no obligation to revise or update any

Partnership with 40-Year Industry Leader Positions ZIVO to Meet Anticipated Global Commercial Demand TROY, Mich.--(BUSINESS WIRE)-- Zivo Bioscience, Inc. (OTCQB: ZIVO) ("ZIVO" or the "Company"), a biotech/agtech R&amp;D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced the signing of a manufacturing agreement with Cyanotech Corporation to grow, cultivate and process ZIVO's proprietary algal biomass for its Zivolife™ product line. ZIVO is advancing Zivolife™ toward commercial applications across animal health, human nutrition and functional ingredients markets. This agreement with Cyanotech, one of the world's most established microalgae producers, represents a significant milestone in ZIVO's commercial readiness as the Company prepares to meet anticipated demand from existing and prospective partners across global markets. A World-Class Production Partner Cyanotech brings unmatched depth of experience and infrastructure to the partnership, including: Over 40 years of continuous microalgae cultivation, operating since 1984 on the Kailua-Kona Coast of Hawaii's Big Island 96-acre production facility at the Natural Energy Laboratory of Hawaii Authority (NELHA), one of the largest dedicated microalgae farms in the world Multi-species expertise with proven commercial-scale cultivation of Spirulina and Haematococcus, and now ZIVO’s proprietary Kelbsormidium Flaccidum, across dietary supplement, nutraceutical and food applications Pristine growing environment located in a designated Biosecure Zone with abundant year-round sunlight, clean air, clean lava-filtered water and low rainfall enabling 12-month production cycles cGMP operations with rigorous third-party quality control and FDA regulatory compliance GRAS (Generally Recognized as Safe) certification for microalgae products intended for food use Proven scale with production volumes that have driven consistent year-over-year growth including recent financial results reflecting nearly 20% revenue growth "Securing Cyanotech as our manufacturing partner is a transformational step for ZIVO," said John Payne, CEO and Chairman of ZIVO Bioscience. "Their decades of operational expertise, scale of production and commitment to quality provide the infrastructure we need to confidently respond to global market demand for Zivolife™. We are building a reliable supply chain for our partners, which is a critical step toward enabling initial commercial revenues." "Cyanotech is proud to partner with ZIVO Bioscience and bring our cultivation expertise to the production of Zivolife™. The agreement provides ZIVO with scalable production capacity to support initial commercial volumes, with the ability to expand as demand increases," said Matthew Custer, President and CEO of Cyanotech Corporation. "ZIVO has developed a compelling proprietary algal biomass with strong consumer appeal, and we look forward to supporting their success." About ZIVO Bioscience ZIVO Bioscience is a research and development company with an intellectual property portfolio comprised of proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques and patented or patent pending inventions for applications in human and animal health. Please visit <a href="https://nam12.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.zivobioscience.com%2F&amp;data=05%7C02%7Claith%40tccmobile.com%7C11c8579ec395418c952708de9042ad5f%7C6e5cfbc3a0c3479980d6411ab1efe6ae%7C0%7C0%7C639106813257770057%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIs

TROY, Mich.--(BUSINESS WIRE)-- ZIVO Bioscience, Inc. (OTCQB: ZIVO), today issued the following letter to shareholders from Chairman, President and Chief Executive Officer John B. Payne. Dear Fellow Shareholders, I am writing to inform you of a significant and carefully considered decision by the Board of Directors of ZIVO Bioscience, Inc. (“ZIVO” or the “Company”): we intend to deregister the Company’s securities with the Securities and Exchange Commission and cease public reporting. This letter explains the reasoning behind this decision, what it means for shareholders, and how it positions ZIVO for its next phase of growth. A Decision Made in the Best Interests of Shareholders After careful deliberation, we have concluded that remaining a public reporting company is no longer in the best interests of our shareholders — particularly at this stage of our development. The costs associated with maintaining a public listing — SEC compliance, legal, financial reporting, insurance and audit fees, exchange listing requirements, and investor relations obligations — represent a significant and ongoing financial burden. For a company of our size, with revenue still in an early stage, these costs consume a disproportionate share of our resources. Simply put, too much of our capital is flowing to third parties to sustain our public status rather than being deployed to build the business and create value for you, our shareholders. Additionally, the repeated need to raise capital to fund public reporting expenses has resulted in ongoing shareholder dilution. Each successive financing round, though necessary to keep the Company operating, has reduced the ownership percentage of our existing shareholders. We believe this cycle does not serve you well, and we are committed to breaking it. Revenue on the Horizon We are at an inflection point on the AgTech vertical. Through our established distribution relationship, we anticipate meaningful revenue from our AgTech product line in the coming months. We have a distribution partner in place and commercial activity advancing. As a non-reporting company, we will be in a better position to retain and accumulate that revenue and cash for the direct benefit of the Company, rather than directing it toward the overhead of public company compliance. Anticipated revenue through our distribution partner, along with the decrease in operating cost, will likely result in positive cash flow (for the first time in the Company’s history). Business Update Our underlying business fundamentals remain strong and continue to progress. In our Animal Health division, major global animal health companies are advancing internal due diligence on our non-antibiotic immune-modulating technology, which has proven efficacious in repeated studies. Production, yield, dose titration and interference studies are underway, and our formal partnership and licensing discussions are anticipated once that data is available. With regard to Avian Influenza, the Department of Agriculture has recently awarded funds to various parties including The University of Georgia. The University of Georgia plans to use our product in various studies to help solve this very serious problem facing the poultry industry. In our AgTech and Human Nutrition segment, our ZIVO LIFE™ microalgae ingredient has generated commercial interest from formulators globally, and our distribution partner is positioned to generate significant near-term revenue. We are increasing production capacity in anticipation of growing demand. Our Commitment to You Our Board of Directors has already taken concrete steps to demonstrate alignment with shareholders: board compensation has been eliminated, and any Board members who invest do so at full market price without discounts or inc

TROY, Mich.--(BUSINESS WIRE)-- ZIVO Bioscience, Inc. (OTCQB: ZIVO), a biotech and agtech R&amp;D company engaged in the development of therapeutic and nutritional products derived from proprietary algal cultures, today issued the following letter to shareholders from Chairman, President and Chief Executive Officer John B. Payne. Dear Fellow Shareholders, I am pleased to provide you with this important update on the significant progress by ZIVO Bioscience and a review of our exciting future direction. Quite simply, this past year has been one of the most pivotal in our history. Our proprietary algae platform has delivered breakthrough results that position ZIVO at the forefront of two rapidly growing markets – human nutrition and animal health – while addressing one of agriculture’s most pressing global challenges: reducing antibiotic use at cost parity and without compromising animal productivity. Breakthrough Scientific Validation Over the past year, we have achieved remarkable validation of our algae technology that we believe fundamentally positions ZIVO as a leader in natural antioxidant solutions. At the request of a prospective major customer, an independent biochemical analysis was conducted on our algae product. The results exceeded our expectations: our algae contains substantial levels of key antioxidants, including Superoxide Dismutase (SOD) and catalase, as well as a rich profile of vitamins, carotenoids, and proteins. Most notably, this preliminary study demonstrated that our algae had, on average, nearly double the activity of SOD in a side-by-side comparison to a competing algae-based product. Together with its abundant beta-carotene and lutein, these exciting results position ZIVO's product as a powerful natural source of antioxidants. We believe this breakthrough definitively sets us apart in the nutraceutical marketplace and positions us as an attractive partner for leading companies seeking validated, high-performance natural ingredients. We are presently in active discussions with major nutraceutical clients, and we anticipate significant commercial commitments in the near term that will materially increase our human health revenues. Animal Health Market Leadership Equally transformative are our advances in the animal health sector, where we believe our data has proven exceptionally compelling. Our algae culture provides critical ingredients in non-antibiotic animal feed formulations that dramatically boost animals' immune systems, helping to prevent or delay the onset of viral, bacterial, and parasitic diseases. Our recent studies in poultry infected with avian influenza have been especially encouraging. In controlled university challenge trials, birds receiving our algae-derived immune modulator showed delayed transmission, lower viral shedding, and faster immune response compared to the control group. These outcomes demonstrate not only strong biological activity, but also real-world potential to slow the spread of one of the industry’s most devastating diseases. This success has generated substantial interest across the industry. We have continued to be approached by global animal health companies, validating both the market demand and the superior performance of our algae technology. Additionally, with such excellent results demonstrated, we intend to negotiate with major companion animal product companies, expanding our addressable market significantly. Massive Market Opportunity By addressing the urgent need for natural, non-antibiotic solutions, ZIVO is targeting some of the fastest-growing and highest-margin segments in animal health. In fact, the markets we are targeting represent multibillion-dollar opportunities: U.S. and Global Market Scale Through 2030 The global animal feed market was valued at $465.

TROY, Mich.--(BUSINESS WIRE)-- ZIVO Bioscience, Inc. (OTCQB: ZIVO), a biotech and agtech R&amp;D company engaged in the development of therapeutic and nutritional products derived from proprietary algal cultures, announces it has entered into a relationship with one of the world’s leading animal health companies to advance ZIVO’s novel immune-boosting compounds for use in multiple poultry market segments. The collaboration is expected to expand over time to address significant unmet needs in other livestock and companion animal species. Initially, ZIVO and its partner have executed two agreements that will govern independent studies designed to validate and expand the use of ZIVO’s proprietary actives as immune-enhancing biologics to complement existing poultry vaccination strategies. The first agreement covers a 42-day study focused on coccidiosis, a parasitic disease that remains a major challenge to poultry producers worldwide. This challenge study is intended to confirm previously demonstrated effects of ZIVO’s compound now co-administered with the collaborator’s vaccine, and will include collecting tissue and plasma samples to evaluate performance parameters not previously examined. This trial will support the regulatory approval process of the USDA’s Center for Veterinary Biologics, as well as to validate the commercial business case and lead to a commercial agreement. Under the second agreement, a study will assess ZIVO’s compounds using a model of various viral diseases of significant consequence to the commercial poultry industry. The particular disease to be studied, which has no cure, is characterized by rapid onset and high mortality rates. The virus was selected for its well-established in vivo model, clear clinical endpoints and short study duration, while serving as a representative model for a range of other viral poultry diseases. This study was prompted by ZIVO’s previously reported data showing reduced severity and spread of low-pathogenic avian influenza (LPAI) in treated birds. Positive outcomes from this trial will lead to a broader research agreement to pursue additional diseases. Applications for treating viruses represent a significant expansion of the therapeutic range and economic value of ZIVO’s novel immune-boosting compounds. Both studies, to be fully funded by the collaborating company, will investigate several ZIVO product candidates for their ability to: Reduce the time between immunization and the onset of protective immunity, Protect birds during the vulnerable period between vaccination and immunity, Enhance the immune response following immunization, and Mitigate the immunosuppressive effects of diseases that leave birds susceptible to secondary infections. “This collaboration supports our strategy to partner with a major animal health company that brings scientific expertise and R&amp;D infrastructure to advance our innovations to global markets efficiently and at scale,” said John Payne, Chairman and Chief Executive Officer of ZIVO Bioscience. “We are aligned with this company on the broad applicability of our immune-modulating technology and its potential to create a disruptive, non-antibiotic therapeutic platform. Adding ZIVO’s therapeutic products to their portfolio would represent an entirely new market for our partner, and the significant prior work we’ve done provides high confidence for success.” About ZIVO Bioscience ZIVO Bioscience, Inc. is a research and development company with an intellectual property portfolio comprised of proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques and patented or patent-pending inventions for applications in human and animal health. Please visit <a href="http://www.zivobioscience.com" rel

TROY, Mich.--(BUSINESS WIRE)-- ZIVO Bioscience, Inc. (OTCQB: ZIVO), a pioneering biotech/agtech R&amp;D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced positive results from its second collaborative study with the University of Delaware evaluating the efficacy of several formulations of ZIVO’s proprietary active ingredients in mitigating the spread of Low Pathogenicity Avian Influenza (LPAI) virus among poultry. Building upon the outcomes of the initial study, this second study aimed to assess and compare the performance of three different ZIVO formulations in both directly challenged and contact-exposed birds. The study affirmed earlier observations that ZIVO's active ingredients may positively influence LPAI transmission dynamics, while identifying the optimal formulation for further testing. In the first arm of the study, which involved birds receiving a direct challenge with LPAI, modest positive trends were observed in viral shedding reduction among ZIVO-treated groups compared with untreated controls. While these differences did not reach statistical significance, the findings suggest potential for ZIVO's formulations to lessen disease severity. The second arm focused on the transmission of the virus from infected birds to naïve birds. Notably, the formulation consisting of a blend of four distinct algal-derived materials demonstrated a slower and less efficient spread of the virus. One bird treated with this combination showed no signs of infection post-exposure, indicating potential protective effects. Brian Ladman, PhD, Principal Investigator at the University of Delaware's Department of Animal and Food Sciences, commented, "Any positive trend observed in these early-stage studies is very encouraging. Delaying transmission, even by a few days, can provide significant benefits to poultry producers by allowing more time to manage high risk or at-risk flocks effectively." "These findings resulting from rigorous testing at the University of Delaware reinforce our commitment to developing sustainable, non-antibiotic solutions for the poultry industry. The insights gained from this study show encouraging trends and identifying a superior formulation will be instrumental in guiding our future research and product optimization efforts. Given the potential impact ZIVO’s product can have on mitigating avian influenza, a widespread issue in the nation’s large poultry industry, we submitted a funding request to the State of Michigan for $5.5 million to further our research. Additionally, we are applying for a portion of the previously announced $100 million Avian Influenza Poultry Innovation Grand Challenge from the USDA," said John Payne, Chairman and CEO of ZIVO Bioscience. ZIVO Bioscience remains dedicated to advancing its pipeline of algal-derived compounds aimed at enhancing poultry health and productivity. The company plans to continue its collaboration with the University of Delaware to further explore and refine these interventions, including a larger scale project focused on a single formulation in order to determine the reproducibility of the observations from the first two studies. About ZIVO Bioscience ZIVO Bioscience, Inc. is a research and development company with an intellectual property portfolio comprised of proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques and patented or patent-pending inventions for applications in human and animal health. Please visit www.zivobioscience.com for more information. Forward Looking Statements Except for any historical information, the matters discussed in this press release contain forward-looking statements within

TROY, Mich.--(BUSINESS WIRE)-- ZIVO Bioscience, Inc. (OTCQB: ZIVO), a pioneering biotech/agtech R&amp;D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces plans for a second collaborative study with the University of Delaware. This new study aims to further explore the potential applications of ZIVO's proprietary active ingredients in mitigating the spread of Low Pathogenicity Avian Influenza (LPAI) virus among poultry. ZIVO’s previous study with the University of Delaware demonstrated a significant reduction in viral shedding and a delay in disease transmission among treated birds. This new study is designed to further optimize formulations and treatment protocols with the goal of enhancing the efficacy of ZIVO’s proprietary active ingredients when applied to real-world poultry production environments. Catalyzed by encouraging findings from completed studies in avian influenza and coccidiosis, ZIVO has attracted interest from several global animal health companies seeking innovative, non-antibiotic solutions to combat disease transmission. This interest underscores the opportunity for ZIVO’s proprietary algal-derived compounds to play a role in improving poultry health and productivity. "The University of Delaware is a preeminent institution in animal science research and we look forward to continuing our collaboration to advance understanding of how our active ingredients can combat avian influenza," said John Payne, Chairman and CEO of ZIVO Bioscience. "The interest from leading animal health companies further validates our approach and commitment to delivering sustainable, healthier solutions at cost parity to the poultry industry." “This newest study represents the next step in what we expect will be a series of studies to thoroughly evaluate the potential of ZIVO's products in various avian influenza applications. By leveraging active components from our proprietary algal cultures in new indications, we aim to develop effective, natural alternatives to traditional treatments, thereby addressing the significant challenges in animal health of cost and drug resistance,” added Mr. Payne. About ZIVO Bioscience ZIVO Bioscience, Inc. is a research and development company with an intellectual property portfolio comprised of proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques and patented or patent-pending inventions for applications in human and animal health. Please visit www.zivobioscience.com for more information. Forward Looking Statements Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including with respect to the Company’s product candidate’s potential to generate revenues and the expected timeframe for results of future studies. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. Although ZIVO believes there is a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks that our strategic partnerships may not facilitate the commercialization or market acceptance of our products; risks that we will be unable to increase production sufficient to meet

BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)-- Zivo Bioscience, Inc. (OTCQB: ZIVO), a pioneering biotech/agtech R&amp;D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced its participation in The Microcap Conference 2025 being held January 28-30, 2025, in Atlantic City, N.J. Management will deliver a corporate presentation and engage in one-on-one meetings with institutional and individual investors to discuss the company’s recent developments, growth strategy, and investment opportunities. Event: The Microcap Conference 2025 Location: Studio 1, Borgata Hotel Casino &amp; Spa Date: Thursday January 30, 2025 Time: 2:30 PM Eastern Time Investors interested in meeting with management can register for the conference here. About ZIVO Bioscience Zivo Bioscience, Inc. is a research and development company with an intellectual property portfolio comprised of proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques and patented or patent pending inventions for applications in human and animal health. Please visit www.zivobioscience.com for more information. View source version on businesswire.com: https://www.businesswire.com/news/home/20250122415215/en/ ZIVO Bioscience Keith Marchiando, Chief Financial Officer (248) 452-9866 x130 kmarchiando@zivobioscience.com Alliance Advisors IR Tirth T. Patel (212) 201-6614 tpatel@allianceadvisors.com Source: Zivo Bioscience, Inc.

Expects to enter into formal negotiations with a global animal health company in January 2025 and to finalize an agreement in the first quarter of 2025 BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)-- Zivo Bioscience, Inc. (OTCQB: ZIVO), a pioneering biotech/agtech R&amp;D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today provided an update on activities related to licensing its product targeting coccidiosis in broiler chickens. Following the announcement in August 2024 of positive results from a 42-day coccidiosis study, the Company has been engaged in discussions with a number of major global animal health companies regarding a potential exclusive license for ZIVO’s product. Prospective licensees are actively pursuing their respective due diligence processes, including technical evaluations, patent reviews and business case assessments. Assuming the satisfactory completion of due diligence, ZIVO expects to enter into formal negotiations next month with the goal of finalizing an agreement in the first quarter of 2025. ZIVO intends to pursue deal terms that includes an upfront payment, milestone payments tied to commercialization targets and a royalty based on product sales. “We are focused on securing an agreement that aligns with our commercialization strategy and delivers long-term value to our shareholders. Although our license dialogues remain ongoing and there can be no assurance we will be successful in negotiating a definitive agreement, we are highly encouraged by the progress we have made over the past four months and by the level of interest expressed by prospective partners. Our product holds potential as a standalone treatment and also can enhance the efficacy of ionophores and vaccines, representing a compelling and transformative value proposition for the poultry industry,” said John B. Payne, Chairman and Chief Executive Officer of ZIVO Biosciences. In addition, building upon last week’s announcement of preliminary efficacy against avian influenza in poultry, the Company reports that it intends to advance development work on its product candidate targeting transmission of Low Pathogenicity Avian Influenza (LPAI) virus among poultry flocks. ZIVO plans to initiate additional studies at the University of Delaware to further optimize dosage and formulation, with the goal of maximizing the product’s efficacy and market readiness. “To date our active ingredients have demonstrated effectiveness against both parasitic and viral diseases. This remarkable versatility provides distinct commercial opportunities, including as a combination product in viral indications,” added Mr. Payne. About Coccidiosis Coccidiosis is a protozoal disease that causes diarrhea, weight loss, decreased performance and increased mortality in poultry. This disease represents a significant economic challenge for the global poultry industry, with the estimated annual costs in excess of $15 billion annually. Products for treating coccidiosis are mostly antibiotic- or ionophore-based, and no significant new commercial technology has been introduced in the past 60 years. The global poultry industry spent approximately $1.1 billion in 2024, and is estimated to grow to $1.5 billion in 2029, on coccidiosis control, primarily using decades-old compounds that industry and consumers alike want to replace due to the risks of developing drug resistance. Coccidiosis is a common disease for chickens, especially among young chicks, and can

BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)-- Zivo Bioscience, Inc. (OTCQB: ZIVO), a pioneering biotech/agtech R&amp;D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, reports favorable results from a study conducted in collaboration with the University of Delaware that evaluated the potential of ZIVO’s proprietary active ingredients to reduce the transmission of Low Pathogenicity Avian Influenza (LPAI) virus among poultry. Key findings of statistical significance from the study include: A reduction in viral titers (viral shedding) in infected birds receiving ZIVO’s products compared with untreated infected controls. A delay in transmission of LPAI when healthy birds were exposed to infected birds, suggesting a slower and less aggressive spread of disease. The two-part controlled study evaluated the efficacy of ZIVO’s proprietary active ingredients, previously shown to be efficacious for mitigating the effects of coccidiosis in broiler chickens, against LPAI. In the first part of the study, infected birds receiving a mixture of ZIVO’s proprietary active ingredients showed an early significant decrease in viral titers compared with untreated, infected controls, thereby reducing amount of detectable virus that was shed. At the end of the study, although not significant in nature, a numerical decrease in virus was noted in birds receiving ZIVO’s product. In the second part, healthy chickens were housed with infected birds, replicating a real-world, high-risk environment for disease transmission. Compared to an untreated control group, birds that received ZIVO’s proprietary active ingredients that were housed with infected birds experienced a statistically significant delay in viral detection. This observed delay suggests that ZIVO’s products limit viral replication within a host. These favorable results indicate that ZIVO’s proprietary active ingredients represent potential preventative measures for reducing the spread of LPAIV in commercial poultry operations and enhancing overall flock health. Multiple products were explored to identify the most effective strategies against LPAI. While some products were better at lowering the viral titer, others were more effective at slowing the spread, suggesting that an optimal product configuration could provide more comprehensive protection. The study’s positive outcomes justify further research and product development, supporting the potential of ZIVO’s pipeline to address both LPAIV infections as well as a broad spectrum of other viral challenges faced by the poultry industry. “We are highly encouraged by the outcomes of this study,” said John B. Payne, Chairman and CEO of ZIVO Bioscience. “The University of Delaware’s findings provide compelling evidence that our feed ingredients could be valuable tools in mitigating the risk of avian influenza outbreaks without the limitations associated with vaccines. Reducing disease transmission can positively impact both animal welfare and the operations of producers. These study results represent a significant milestone in our efforts to deliver science-driven, sustainable solutions to address serious challenges facing the global poultry industry.” “This study sponsored by ZIVO Bioscience enabled us to evaluate novel interventions to provide immune support for poultry,” said Brian Ladman, Ph.D., Principal Investigator at the University of Delaware’s Department of Animal and Food Sciences. “The findings demonstrate that further investigation into ZIVO’s active ingredients to safeguard poultry flocks against viral outbreaks is warranted. I look forward to continuing to work with ZIVO to identify novel solutions to this critical public health issue.” “W